Irvine-based Edwards Lifesciences Corp. today announced newly presented data from several of its clinical trials. The data, presented at the annual New York Valves 2026 conference, included seven-year benchmark results from its Partner 3 trial, as well as new findings from its Early TAVR trial. Both trials are using Edwards’ Sapien 3 transcatheter heart valve and “strengthen the evidence base” for the platform, according to the company. “Our exp…
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.